Objective-Although coronary perivascular adipose tissue (PVAT) may play important roles as a source of inflammation, the association of coronary PVAT inflammation and coronary hyperconstricting responses remains to be examined. We addressed this important issue in a porcine model of coronary hyperconstricting responses after drug-eluting stent implantation with 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomographic imaging. Approach and Results-An everolimus-eluting stent (EES) was randomly implanted in pigs into the left anterior descending or the left circumflex coronary artery while nonstented coronary artery was used as a control. After 1 month, coronary vasoconstricting responses to intracoronary serotonin (10 and 100 μg/kg) were examined by coronary angiography in vivo, followed by in vivo and ex vivo 18 F-FDG positron emission tomographic/computed tomographic imaging. Coronary vasoconstricting responses to serotonin were significantly enhanced at the EES edges compared with the control site (P<0.01; n=40). Notably, in vivo and ex vivo 18 F-FDG positron emission tomographic/computed tomographic imaging and autoradiography showed enhanced 18 F-FDG uptake and its accumulation in PVAT at the EES edges compared with the control site, respectively (both P<0.05). Furthermore, histological and reverse transcription polymerase chain reaction analysis showed that inflammatory changes of coronary PVAT were significantly enhanced at the EES edges compared with the control site (all P<0.01). Importantly, Rho-kinase expressions (ROCK1/ROCK2) and Rho-kinase activity (phosphorylated myosin phosphatase target subunit-1) at the EES edges were significantly enhanced compared with the control site. Conclusions-These results indicate for the first time that inflammatory changes of coronary PVAT are associated with drug-eluting stent-induced coronary hyperconstricting responses in pigs in vivo and that 18 F-FDG positron emission tomographic imaging is useful for assessment of coronary PVAT inflammation. Visual Overview-An online visual overview is available for this article.
T he widespread use of drug-eluting stents (DES) for percutaneous coronary intervention has markedly reduced the risk of restenosis and repeated revascularization. 1 However, they cause unfavorable effects, such as stent thrombosis 2, 3 and coronary hyperconstricting responses [4] [5] [6] [7] [8] not only in response to acetylcholine 4 but also to atrial pacing 7 and exercise. 8 We have previously demonstrated that activation of Rho-kinase, a molecular switch for vascular smooth muscle contraction, is a central mechanism of coronary spasm in animals and humans [8] [9] [10] and that Rho-kinase also plays a key role in the pathogenesis of coronary hyperconstricting responses after DES implantation in animals [11] [12] [13] and humans. 4 We and others have recently demonstrated that adventitial inflammatory changes play important roles in the pathogenesis of coronary spasm in pigs and humans. 9, 10, 14, 15 Furthermore, we have recently demonstrated that enhanced adventitial vasa vasorum formation after DES implantation is associated with coronary hyperconstricting responses through Rho-kinase activation in pigs in vivo. 13 The perivascular components, such as perivascular adipose tissue (PVAT) and vasa vasorum, have recently attracted much attention as sources of vascular inflammation. 16 PVAT is regarded as an active endocrine and paracrine organ that September 2017 produces a variety of cytokines (eg, interleukin 1β [IL-1β], IL-6, and monocyte chemotactic protein-1). 16 It has been shown that enhanced PVAT inflammation promotes atherosclerosis. 17 Furthermore, epicardial adipose tissue volume measured by cardiac computed tomography (CT) is related to coronary plaque burden 18 and is also significantly associated with cardiovascular events. 19 We have recently demonstrated that coronary PVAT volume is increased at the spastic coronary segment of patients with vasospastic angina (VSA) by CT coronary angiography. 20 Currently, most studies that examined biological factors released from coronary PVAT used experiments using ex vivo vessel rings. 21, 22 However, the association and imaging of coronary PVAT inflammation and coronary hyperconstricting responses in vivo remain to be examined. 18 F-fluorodeoxyglucose positron emission tomography ( 18 F-FDG PET) has been clinically used to detect inflammation because it reflects the metabolic activity of glucose, which is a process known to be enhanced in inflamed tissue. 23 Thus, 18 F-FDG PET can noninvasively image the metabolic activity in perivascular, visceral, and subcutaneous fat tissue and could serve as a surrogate marker of fat tissue inflammation. 24, 25 However, it remains to be examined whether 18 F-FDG PET can detect coronary PVAT inflammation in the pathogenesis of coronary hyperconstricting responses.
In the present study, we thus examined whether inflammatory changes of coronary PVAT is associated with DESinduced coronary hyperconstricting responses in pigs in vivo and if so, whether 18 F-FDG PET can detect coronary PVAT inflammation.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
Everolimus-eluting stent (EES) was randomly implanted into the left anterior descending or the left circumflex coronary arteries in 10 pigs (Figure 1 ). The details of stent implantation procedure are shown in Table I in the online-only Data Supplement.
Coronary Vasomotion After Stent Implantation
At 1 month after stent implantation, there was no in-stent restenosis at the implantation sites ( Figure 2A ; Table II in the online-only Data Supplement). Coronary hyperconstricting responses to intracoronary serotonin were noted at the proximal and the distal edges of the EES site ( Figure 2B ), which were abolished by pre-treatment with intracoronary hydroxyfasudil, a selective Rho-kinase inhibitor ( Figure 2C ). Coronary angiography and quantitative coronary angiography showed that coronary vasoconstricting responses to serotonin were significantly enhanced at the EES edges compared with the control site ( Figure 2D ), whereas endothelium-independent and -dependent coronary vasodilating responses to nitroglycerin and bradykinin (regardless of the presence or absence of N G -monomethyl-L-arginine), respectively, were comparable between the EES edges and the control site ( Figure I in the online-only Data Supplement).
Assessment of FDG Uptake in Coronary PVAT at the Stent Implantation Site and the Stent Edge by In Vivo and Ex Vivo PET/CT
In vivo 18 F-FDG PET/CT imaging showed that as compared with the control site, 18 F-FDG uptake was enhanced at the EES site at 1 month after stent implantation ( Figure IIA and IIB in the online-only Data Supplement). In addition, ex vivo 18 F-FDG PET/CT imaging showed that as compared with the control site ( Figure 3A-3D ), 18 F-FDG uptake was markedly enhanced at the EES site ( Figure 3E -3H) at 1 month after stent implantation. In the magnified images, 18 F-FDG uptake extended from the EES implantation site to the proximal and distal edge segments ( Figure 3H ). Quantitative analysis of in vivo 18 F-FDG PET/CT imaging showed that the extent of target-to-background ratio (TBR) of coronary PVAT was significantly increased at the EES edges as compared with the control site ( Figure IIC in the online-only Data Supplement). Quantitative analysis of ex vivo 18 F-FDG PET/CT imaging showed that, at the stent implantation site, the extent of TBR of coronary PVAT was significantly increased at the EES implantation site as compared with the control site, where there was a significant positive correlation between the extent of TBR and that of inflammatory changes ( Figure 3I and 3J) . Similarly, the extent of TBR of coronary PVAT at the EES edges was significantly higher compared with the control site in ex vivo 18 F-FDG PET/CT imaging ( Figure 3K ). Importantly, there was a significant positive correlation between TBR of coronary PVAT at the EES edges and the extent of serotonin-induced coronary vasoconstriction ( Figure 3L ).
Autoradiography Assessment of FDG Accumulation in Coronary PVAT at the Stent Edges
Autoradiography showed that as compared with the control site ( Figure 4A and 4B), 18 F-FDG accumulation was markedly enhanced at the EES edges ( Figure 4C and 4D) at 1 month after stent implantation. Furthermore, 18 F-FDG accumulation extended from the adventitia to coronary PVAT at the EES edges ( Figure 4C and 4D). Quantitative evaluation showed that target-to-normal ratio of the PVAT was significantly increased at the EES edges as compared with the control site ( Figure 4E ). There was a significant positive correlation between target-to-normal ratio of coronary PVAT and the extent of serotonin-induced coronary vasoconstriction at the EES edges ( Figure 4F ). 
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Histomorphological Analysis of the Coronary Artery at the Stent Edge
No differences in histomorphometric parameters of the coronary artery were noted between the control site and the EES edges at 1 month after EES implantation (Table III in 
Inflammatory Changes of Coronary PVAT at the Stent Implantation Site and the Stent Edges
At the EES implantation sites, the extent of inflammatory changes of the coronary artery was significantly increased as compared with the control site ( Figure IIIA -IIIG in the online-only Data Supplement). Similarly, at the stent edges, inflammatory cells infiltration in coronary PVAT was noted mainly at the EES edges as compared with the control site ( Figure 5A-5H ). The numbers of CD68-positive cells (macrophages; Figure 5C , 5D, and 5I) and IL-1β-positive cells ( Figure 5E , 5F, and 5I) were significantly increased, whereas adiponectin-positive areas ( Figure 5G , 5H, and 5I) were significantly reduced at the EES edges as compared with the control site. Furthermore, there were significant correlations between the numbers of CD68-positive cells, IL-1β-positive cells, or adiponectin-positive areas in the PVAT and the extent of serotonin-induced coronary vasoconstriction at the EES edges ( Figure 6A-6C ). In addition, the adipocyte diameter was significantly increased at the EES edges as compared with the control site ( Figure 5J-5L ). The extent of serotonininduced coronary vasoconstriction and inflammatory parameters in coronary PVAT at the distal edges tended to be higher as compared with the proximal edges (Table IV in 
Expressions of Inflammation-Related Molecules in Coronary PVAT at the Stent Edges
mRNA expressions of IL-1β, IL-6, and tumor necrosis factor-α were significantly increased whereas that of adiponectin was significantly suppressed at the EES edges as compared with the control site ( Figure 5M ). Furthermore, there were significant correlations between the extent of IL-1β or adiponectin expression (but not that of IL-6 or tumor necrosis factor-α expression) in coronary PVAT and that of serotonin-induced coronary vasoconstriction at the EES edges ( Figure 6D-6G ).
Rho-Kinase Activity and Cell Proliferation
Immunoreactivities of Rho-kinase (ROCK1 and ROCK2) and phosphorylated myosin phosphatase target subunit-1 (a marker of Rho-kinase activity) were all enhanced mainly in the medial vascular smooth muscle cells (VSMC) at the EES edges as compared with the control site ( Figure 7A-7F ). In the semiquantitative analysis, the extent of Rho-kinase expressions (ROCK1/2) and Rho-kinase activity (phosphorylated myosin phosphatase target subunit-1) at the EES edges was significantly enhanced compared with the control site ( Figure 7G-7I ). The number of Ki67-positive cells in VSMC and coronary PVAT was comparable between the EES edges and the control site ( Figure IV in the online-only Data Supplement).
Discussion
The major findings of the present study were that (1) inflammatory changes of coronary PVAT were significantly enhanced at the EES edges as compared with the control site after DES implantation in pigs in vivo, (2) there were significant correlations between inflammatory changes of the PVAT and DESinduced coronary hyperconstricting responses, and (3) 18 F-FDG PET imaging was useful to detect inflammatory changes of the PVAT (Graphic Abstract). To the best of our knowledge, the present study demonstrates for the first time that inflammatory changes of coronary PVAT are associated with DES-induced coronary hyperconstricting responses in vivo.
DES-Induced Inflammatory Changes of Coronary PVAT
Although DES are now widely used for percutaneous coronary intervention, they have no beneficial prognostic impact as compared with bare-metal stents. 26 Notably, 30% of patients with stable angina were still symptomatic at 1 year after successful percutaneous coronary intervention. 27 In addition, new or worsening angina was also documented among patients who underwent successful percutaneous coronary intervention with EES, one of the most promising DES. 28 Importantly, impaired coronary vasomotion after DES implantation has been reported 4,7-9,11-13 as a cause of new or unremitting angina and cardiac arrest and as a predictor of impaired vascular healing and subsequent stent thrombosis. 3 Thus, DES-induced coronary hyperconstricting responses are an emerging clinical problem for their long-term safety.
PVAT is an active endocrine and paracrine organ that produces a variety of cytokines (eg, IL-1β, IL-6, and monocyte chemotactic protein-1). 16 Notably, a recent study showed that biological factors released from coronary PVAT could potentiate coronary vasoconstriction. 22 We also have previously demonstrated that adventitial inflammation induced by chronic treatment with IL-1β induces coronary vasospastic activity in pigs. 8, 14 In addition, we have recently demonstrated that adventitial vasa vasorum formation is enhanced at the spastic coronary segment in both the porcine model and in the patients with VSA. 13, 29, 30 Thus, in the present study, we focused on inflammatory changes of coronary PVAT in the pathogenesis of DES-induced coronary hyperconstricting responses. We found that in coronary PVAT at the DES edges, macrophages infiltration and expression of proinflammatory cytokines (eg, IL-1β, IL-6, and tumor necrosis factor-α) were enhanced while adiponectin was downregulated, associated with coronary hyperconstricting responses. Importantly, there were positive correlations between the extents of inflammatory changes in the PVAT and that of coronary vasoconstriction, suggesting important roles of PVAT inflammation in the pathogenesis of DES-induced coronary hyperconstricting responses.
Role of the Adventitia and PVAT of the Coronary Artery for Rho-Kinase Activation in the Pathogenesis of Coronary Hyperconstricting Responses
We have previously demonstrated that enhanced Rho-kinase activity plays a central role in the molecular mechanisms of coronary artery spasm in animals and humans. 4, [8] [9] [10] [11] [12] [13] 15 Rho-kinase suppresses myosin phosphatase activity by phosphorylating myosin phosphatase target subunit-1 and thus augments VSMC contraction. 10 We also have previously shown that intracoronary administration of fasudil or hydroxyfasudil, selective Rho-kinase inhibitors, substantially inhibits coronary spasm in pigs 9,10,15 and humans. 8, 10 In addition, we demonstrated that coronary hyperconstricting responses can be induced without endothelial dysfunction in a porcine model with adventitial application of IL-1β through Rho-kinase activation. In fact, in the present study, endothelium-dependent vasodilating responses to bradykinin and the degree of endothelial surface coverage were comparable between the EES edges and the control site in this study, indicating that endothelium is functionally and structurally preserved at the EES edges as compared with the control site. The present study also showed that at the EES edges, the expression and activity of Rho-kinase are markedly enhanced, mainly in the medial VSMC. In addition, we have recently demonstrated that adventitial vasa vasorum formation is enhanced at the spastic coronary segment in a porcine model and in patients with VSA. 13, 29, 30 Thus, VSMC hypercontraction induced by adventitial and perivascular inflammation through Rho-kinase activation, rather than endothelial dysfunction, plays a major role in the pathogenesis of coronary hyperconstricting responses.
PET Imaging of Coronary PVAT Inflammation
18
F-FDG PET is used for detecting inflammation because it reflects the metabolic activity of glucose that is enhanced in inflamed tissue. 25 18 F-FDG PET can noninvasively visualize the metabolic activity of perivascular, visceral, and subcutaneous fat tissue and thus may serve as a surrogate marker of fat tissue inflammation. 24, 25 Furthermore, it has been reported that inflammatory activity of coronary PVAT evaluated by 18 F-FDG PET is associated with coronary atherosclerosis. 31 In the present study, 18 F-FDG PET/CT imaging showed that 18 F-FDG uptake was significantly enhanced at the EES edges as compared with the control site. Importantly, there were positive correlations between the extent of 18 F-FDG uptake and that of coronary vasoconstriction or inflammatory changes in coronary PVAT (eg, macrophage infiltration and IL-1β expression). The 18 F-FDG PET imaging is based on the higher metabolic glucose demand of macrophages than that of adjacent cells. 25 In the present study, there was a significant positive correlation between 18 F-FDG uptake in ex vivo PET and autoradiography at the EES and the control vasoconstriction site and macrophages density in coronary PVAT. Furthermore, there were significant correlations between 18 F-FDG uptake at the EES edges and the control sites and changes in inflammation-related mediators (eg, IL-1β, IL-6, tumor necrosis factor-α, and adiponectin), which are secreted from inflamed adipose tissue with infiltrating macrophages. Thus, the present results suggest that 18 F-FDG uptake could reflect the extent of inflammatory changes in coronary PVAT associated with coronary hyperconstricting responses after DES implantation. In addition, the present results indicate that 18 F-FDG PET imaging is clinically useful for examining the presence and severity of coronary artery disease with coronary hyperconstricting responses, such as VSA and angina after DES implantation. To address this issue, we are now conducting a clinical study to evaluate inflammatory changes of coronary PVAT by 18 F-FDG PET imaging in patients with VSA.
Study Limitations
Several limitations should be mentioned for the present study. First, in the present study, the PET/CT scanner used for in vivo 18 F-FDG imaging did not have enough high resolution to visually discriminate coronary PVAT inflammation after EES implantation. However, as shown in Figure II in the online-only Data Supplement, we were able to demonstrate the significant difference between the EES edges and control site by using quantitative analysis of in vivo 18 F-FDG PET/CT imaging. Second, because bare-metal stent was not used in the present study, we were unable to address the difference in vasoconstriction and inflammatory changes between bare-metal stent and DES. However, we and others have previously demonstrated that the extent of vasoconstriction and inflammatory changes after stent implantation are enhanced with DES as compared with baremetal stent. 11, 32, 33 Third, in the present study, we used a relatively small number of animals although our present findings with 18 F-FDG PET have statistical significance as in our previous study. 11 Fourth, because the present study was performed in normal male pigs without pre-existing coronary atherosclerotic lesions, caution should be needed when extrapolating the present findings to humans. Fifth, because it was difficult to perform immunostainings of the resin-embedded sections of the stent implantation sites, we were unable to elucidate the detailed mechanisms of PVAT inflammation at the stent implantation sites. Finally, although we demonstrated the association between coronary PVAT inflammation and coronary hyperconstricting responses, their causal relationships remain to be fully examined.
Conclusions
The present study demonstrates for the first time that inflammatory changes in coronary PVAT are associated with DESinduced coronary hyperconstricting responses in pigs in vivo and that 18 F-FDG PET imaging may be useful for assessment of coronary PVAT inflammation.
